Synta Pharmaceuticals Corp. (NASDAQ:SNTA)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that address severe medical conditions with potential markets, including cancer and chronic inflammatory diseases.


Player Avatar zzlangerhans (99.85) Submitted: 9/27/2012 12:48:04 AM : Underperform Start Price: $8.12 SNTA Score: +13.83

I've lost track of how many times I've dipped into the Synta well for points. This is definitely my top performer for number of positive picks, accuracy, and total points but ironically I've never had any real skin in the Synta game. Hsp90 inhibitor ganetespib is certainly in a lot of mid-stage trials but thus far in 2012 we haven't seen the kind of exciting interim data that management led us to expect. There's certainly a lot more info to come, but with Synta's poor developmental track record so far I see a market cap of 450M as excessively optimistic.

Member Avatar miteycasey (30.12) Submitted: 10/16/2012 6:59:43 PM
Recs: 0

you have both the bull and bear pitches for this stock...kinda funny.

Featured Broker Partners